IL1B and myocardial infarction: Targeting innate immunity with antibodies against interleukin-1 beta (IL-1β) led to reduced recurrent cardiovascular events in patients with previous myocardial infarction, independent of lipid lowering [131], suggesting that CVD is driven by inflammation.